Shuntaro Obi

9.4k total citations · 2 hit papers
81 papers, 4.3k citations indexed

About

Shuntaro Obi is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Shuntaro Obi has authored 81 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hepatology, 34 papers in Epidemiology and 22 papers in Surgery. Recurrent topics in Shuntaro Obi's work include Hepatocellular Carcinoma Treatment and Prognosis (57 papers), Liver Disease Diagnosis and Treatment (31 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers). Shuntaro Obi is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (57 papers), Liver Disease Diagnosis and Treatment (31 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers). Shuntaro Obi collaborates with scholars based in Japan, United States and Italy. Shuntaro Obi's co-authors include Masao Omata, Shinpei Sato, Shuichiro Shiina, Takuma Teratani, Haruhiko Yoshida, Ryosuke Tateishi, Yukihiro Koike, Takao Kawabe, Tomonori Fujishima and Masatoshi Imamura and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Shuntaro Obi

76 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Controlled Trial of Radiofrequency Ablation With Ethanol Injection for Small Hepatocellular Carcinoma

2005 656 citations Shuichiro Shiina, Takuma Teratani et al. profile →
Percutaneous radiofrequency ablation for hepatocellular carcinoma

2005 630 citations Ryosuke Tateishi, Shuichiro Shiina et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shuntaro Obi Japan	28	3.5k	2.1k	987	619	572	81	4.3k
Min-Shan Chen China	32	3.3k 0.9×	1.9k 0.9×	1.3k 1.3×	1.4k 2.2×	896 1.6×	58	5.3k
Takuma Teratani Japan	23	3.0k 0.8×	2.0k 0.9×	952 1.0×	477 0.8×	315 0.6×	59	3.6k
Alessandro Granito Italy	49	2.9k 0.8×	2.6k 1.3×	1.3k 1.3×	544 0.9×	375 0.7×	149	4.8k
Massimo Iavarone Italy	30	2.7k 0.8×	2.2k 1.1×	493 0.5×	454 0.7×	413 0.7×	130	3.5k
Sadahisa Ogasawara Japan	26	3.0k 0.9×	1.4k 0.6×	665 0.7×	1.3k 2.0×	547 1.0×	137	4.1k
Masami Minagawa Japan	18	3.5k 1.0×	1.6k 0.7×	1.7k 1.7×	1.3k 2.1×	644 1.1×	30	4.2k
Baogang Peng China	32	1.7k 0.5×	880 0.4×	810 0.8×	1.2k 1.9×	875 1.5×	103	3.6k
Susumu Yamasaki Japan	31	2.7k 0.8×	1.4k 0.7×	2.2k 2.3×	1.6k 2.7×	497 0.9×	66	4.7k
Jin Sub Choi South Korea	35	2.4k 0.7×	1.4k 0.6×	1.9k 2.0×	1.4k 2.3×	520 0.9×	169	4.0k
Olivier Séror France	26	1.8k 0.5×	1.2k 0.6×	582 0.6×	335 0.5×	266 0.5×	102	2.7k

Countries citing papers authored by Shuntaro Obi

Since Specialization

Citations

This map shows the geographic impact of Shuntaro Obi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuntaro Obi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuntaro Obi more than expected).

Fields of papers citing papers by Shuntaro Obi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuntaro Obi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuntaro Obi. The network helps show where Shuntaro Obi may publish in the future.

Co-authorship network of co-authors of Shuntaro Obi

This figure shows the co-authorship network connecting the top 25 collaborators of Shuntaro Obi. A scholar is included among the top collaborators of Shuntaro Obi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuntaro Obi. Shuntaro Obi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Obi, Shuntaro, Miho Kanda, Yoshihiko Ooka, et al.. (2023). The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population. Hepatology International. 17(3). 562–572.

Amano, Hiroyuki, Tatsuo Kanda, Hitoshi Mochizuki, et al.. (2021). The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection. Viruses. 13(11). 2216–2216.

Ohki, Takamasa, Koki Sato, Mayuko Kondo, et al.. (2020). Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs - Real World Outcomes. 7(2). 141–149. 28 indexed citations

Kudo, Masatoshi, Kazuomi Ueshima, Yasutaka Chiba, et al.. (2019). Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer. 8(6). 505–519. 12 indexed citations

Obi, Shuntaro, Takahisa Sato, Shinpei Sato, et al.. (2019). The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatology International. 13(2). 199–204. 26 indexed citations

Kudo, Masatoshi, Sadahisa Ogasawara, Shuntaro Obi, et al.. (2018). Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet. Gastroenterology & hepatology. 3(6). 424–432. 203 indexed citations

Kawai, Toshihiro, Yoko Yashima, Takafumi Sugimoto, et al.. (2016). Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a retrospective study. World Journal of Surgical Oncology. 14(1). 52–52. 7 indexed citations

Takata, Akemi, Motoyuki Otsuka, Takeshi Yoshikawa, et al.. (2012). MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology. 57(1). 162–170. 85 indexed citations

Kaneko, Shuichi, Junji Furuse, Masatoshi Kudo, et al.. (2012). Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatology Research. 42(6). 523–542. 39 indexed citations

10.

Ohkawa, Ryunosuke, Hayato Nakagawa, Yumiko Satoh, et al.. (2012). Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. Journal of Hepatology. 57(2). 330–336. 14 indexed citations

11.

Shiina, Shuichiro, Ryosuke Tateishi, Masatoshi Imamura, et al.. (2012). Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors. Liver International. 32(9). 1434–1442. 57 indexed citations

12.

Imamura, Jun, Ryosuke Tateishi, Shuichiro Shiina, et al.. (2008). Neoplastic Seeding After Radiofrequency Ablation for Hepatocellular Carcinoma. The American Journal of Gastroenterology. 103(12). 3057–3062. 81 indexed citations

13.

Koike, Yukihiro, Haruhiko Yoshida, Shuichiro Shiina, et al.. (2007). Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatology International. 1(2). 295–301. 11 indexed citations

14.

Tateishi, Ryosuke, Shuichiro Shiina, Haruhiko Yoshida, et al.. (2006). Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 44(6). 1518–1527. 126 indexed citations

15.

Akamatsu, Masatoshi, Haruhiko Yoshida, Shuichiro Shiina, et al.. (2006). Sustained viral response prolonged survival of patients with C‐viral hepatocellular carcinoma. Liver International. 26(5). 536–542. 14 indexed citations

16.

Obi, Shuntaro, Haruhiko Yoshida, Tadao Unuma, et al.. (2006). Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 106(9). 1990–1997. 212 indexed citations

17.

Fujishima, Tomonori, Haruhiko Yoshida, Shuntaro Obi, et al.. (2005). Analysis of factors influencing hepatocellular carcinoma detection: efficient use of computed tomography during arterial portography and during hepatic arteriography. Journal of Gastroenterology. 40(3). 266–273. 12 indexed citations

18.

Akamatsu, Masatoshi, Haruhiko Yoshida, Shuntaro Obi, et al.. (2004). Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver International. 24(6). 625–629. 39 indexed citations

19.

Tanaka, Yasuo, Masaki Takayanagi, Yasushi Shiratori, et al.. (2003). Congenital absence of portal vein with multiple hyperplastic nodular lesions in the liver. Journal of Gastroenterology. 38(3). 288–294. 41 indexed citations

20.

Shiina, Shuichiro, Masatoshi Imamura, Shuntaro Obi, et al.. (1997). Percutaneous microwave coagulation therapy for liver tumors. Journal of Microwave Surgery. 15. 65–69. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact